A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Amy Schumer has recently spoken up about her horrific experience with Ozempic. The Trainwreck star recalled using weight-loss medication almost three years ago in 2022 but she stopped the once ...

Experts have claimed GLP-1 medications, such as Ozempic, and Wegovy may help lessen or even stop “food noise” by slowing down digestion and reducing cravings. Winfrey continued: “I realized the very ...

Novo Nordisk recently published favorable results from the FLOW renal outcomes trial, which found that Ozempic (semaglutide) 1.0 mg lowered the risk of kidney disease progression and kidney and ...

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist, or GLP-1 RA, known as semaglutide. The latest FDA approval makes the medication the first GLP-1 treatment option for people with type ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...